| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
|
Eur J Cancer
|
2009
|
77.71
|
|
2
|
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
|
N Engl J Med
|
2012
|
52.99
|
|
3
|
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
|
Nat Med
|
2004
|
22.96
|
|
4
|
Nivolumab plus ipilimumab in advanced melanoma.
|
N Engl J Med
|
2013
|
17.53
|
|
5
|
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
|
J Clin Oncol
|
2010
|
17.13
|
|
6
|
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
|
N Engl J Med
|
2003
|
16.62
|
|
7
|
Analysis of circulating tumor DNA to monitor metastatic breast cancer.
|
N Engl J Med
|
2013
|
13.22
|
|
8
|
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
|
N Engl J Med
|
1996
|
11.72
|
|
9
|
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
|
Proc Natl Acad Sci U S A
|
2005
|
10.89
|
|
10
|
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
|
N Engl J Med
|
2011
|
8.93
|
|
11
|
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
|
J Clin Oncol
|
2003
|
8.31
|
|
12
|
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
|
Cancer Res
|
2006
|
8.21
|
|
13
|
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
|
Clin Cancer Res
|
2014
|
8.11
|
|
14
|
Cell-free nucleic acids as biomarkers in cancer patients.
|
Nat Rev Cancer
|
2011
|
7.69
|
|
15
|
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
|
Proc Natl Acad Sci U S A
|
2007
|
7.49
|
|
16
|
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.
|
Nature
|
2013
|
7.42
|
|
17
|
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
|
Lancet
|
2009
|
6.65
|
|
18
|
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
|
J Clin Oncol
|
2002
|
6.51
|
|
19
|
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
|
J Clin Oncol
|
2008
|
4.09
|
|
20
|
Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing.
|
Sci Transl Med
|
2012
|
3.92
|
|
21
|
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
|
Lancet Oncol
|
2013
|
3.70
|
|
22
|
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.
|
Med Oncol
|
2010
|
3.06
|
|
23
|
Sample sizes based on the log-rank statistic in complex clinical trials.
|
Biometrics
|
1988
|
2.97
|
|
24
|
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.
|
Gynecol Oncol
|
2011
|
2.67
|
|
25
|
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.
|
Am J Obstet Gynecol
|
1994
|
2.50
|
|
26
|
FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina.
|
Semin Surg Oncol
|
1994
|
2.10
|
|
27
|
Reliability and validity of the functional assessment of cancer therapy-ovarian.
|
J Clin Oncol
|
2001
|
2.05
|
|
28
|
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
|
Clin Cancer Res
|
2010
|
1.85
|
|
29
|
Issues in using progression-free survival when evaluating oncology products.
|
J Clin Oncol
|
2009
|
1.78
|
|
30
|
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
|
Cancer Res
|
2013
|
1.78
|
|
31
|
Overall survival and PD-L1 expression in metastasized malignant melanoma.
|
Cancer
|
2010
|
1.68
|
|
32
|
Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.
|
J Clin Oncol
|
2009
|
1.53
|
|
33
|
Role of cytoreductive surgical treatment in the management of advanced ovarian cancer.
|
Cancer Treat Rep
|
1979
|
1.50
|
|
34
|
Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer.
|
Int J Cancer
|
2013
|
1.27
|
|
35
|
Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
|
J Clin Oncol
|
1992
|
1.26
|
|
36
|
Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells.
|
Cancer Res
|
2010
|
1.24
|
|
37
|
The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
|
PLoS One
|
2013
|
1.22
|
|
38
|
Immunotherapy for ovarian cancer: what's next?
|
J Clin Oncol
|
2010
|
1.17
|
|
39
|
Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
|
J Clin Oncol
|
1992
|
1.15
|
|
40
|
Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy.
|
Clin Immunol
|
2008
|
1.12
|
|
41
|
Dose-dense chemotherapy improves mechanisms of antitumor immune response.
|
Cancer Res
|
2012
|
0.99
|
|
42
|
Medicine. Keeping tabs on tumor DNA.
|
Science
|
2010
|
0.98
|
|
43
|
Designing complex group sequential survival trials.
|
Stat Med
|
2002
|
0.97
|
|
44
|
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
|
Int J Mol Sci
|
2016
|
0.90
|
|
45
|
STATing the importance of immune modulation by platinum chemotherapeutics.
|
Oncoimmunology
|
2012
|
0.89
|
|
46
|
Circulating cell-free nucleic acids: promising biomarkers of hepatocellular carcinoma.
|
Semin Oncol
|
2012
|
0.89
|
|
47
|
The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
|
J Immunother
|
2009
|
0.88
|
|
48
|
Immunotherapy for ovarian cancer: recent advances and perspectives.
|
Curr Opin Oncol
|
2014
|
0.82
|
|
49
|
Repopulation of ovarian cancer cells after chemotherapy.
|
Cancer Growth Metastasis
|
2013
|
0.82
|
|
50
|
The role of immune checkpoint inhibition in the treatment of ovarian cancer.
|
Gynecol Oncol Res Pract
|
2016
|
0.81
|
|
51
|
Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy.
|
Cancers (Basel)
|
2012
|
0.77
|
|
52
|
Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response.
|
Cancer Immunol Immunother
|
2012
|
0.77
|